EXEL vs EXPI
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a StrongBuy and EXPI is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EXEL’s FA Score shows that 1 FA rating(s) are green whileEXPI’s FA Score has 1 green FA rating(s).
- EXEL’s FA Score: 1 green, 4 red.
- EXPI’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EXEL’s TA Score shows that 6 TA indicator(s) are bullish while EXPI’s TA Score has 4 bullish TA indicator(s).
- EXEL’s TA Score: 6 bullish, 4 bearish.
- EXPI’s TA Score: 4 bullish, 4 bearish.
Price Growth
EXEL (@Biotechnology) experienced а +3.43% price change this week, while EXPI (@Real Estate Development) price change was +1.02% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +8.19%. For the same industry, the average monthly price growth was -3.08%, and the average quarterly price growth was -10.41%.
The average weekly price growth across all stocks in the @Real Estate Development industry was +0.85%. For the same industry, the average monthly price growth was -1.78%, and the average quarterly price growth was -5.89%.
Reported Earning Dates
EXEL is expected to report earnings on Aug 12, 2025.
EXPI is expected to report earnings on Jul 30, 2025.
Industries' Descriptions
@Biotechnology (+8.19% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Real Estate Development (+0.85% weekly)Activities range from the renovation and re-lease of existing buildings to the purchase of raw land and the sale of developed land or parcels to others. Demand for land development business is driven by GDP growth, employment rates, interest rates, and access to/cost of capital. For individual companies in this industry, proper cost estimation and successful bidding play critical roles in their profitability. Large companies could potentially have greater access to capital, while smaller companies can specialize in a specific geographic area or market niche. CBRE Group, VICI Properties Inc and Brookfield Property Partners L.P. are some of the large companies in this industry.
| EXEL | EXPI | EXEL / EXPI | |
| Capitalization | 10.3B | 1.57B | 656% |
| EBITDA | 719M | 3.63M | 19,785% |
| Gain YTD | 12.402 | -22.015 | -56% |
| P/E Ratio | 21.27 | 369.00 | 6% |
| Revenue | 2.17B | 4.28B | 51% |
| Total Cash | 1.11B | 127M | 875% |
| Total Debt | 191M | 10K | 1,910,000% |
EXEL | EXPI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 27 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 22 | 90 | |
SMR RATING 1..100 | 41 | 91 | |
PRICE GROWTH RATING 1..100 | 39 | 81 | |
P/E GROWTH RATING 1..100 | 90 | 2 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EXEL's Valuation (50) in the Biotechnology industry is in the same range as EXPI (50) in the Advertising Or Marketing Services industry. This means that EXEL’s stock grew similarly to EXPI’s over the last 12 months.
EXEL's Profit vs Risk Rating (22) in the Biotechnology industry is significantly better than the same rating for EXPI (90) in the Advertising Or Marketing Services industry. This means that EXEL’s stock grew significantly faster than EXPI’s over the last 12 months.
EXEL's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for EXPI (91) in the Advertising Or Marketing Services industry. This means that EXEL’s stock grew somewhat faster than EXPI’s over the last 12 months.
EXEL's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for EXPI (81) in the Advertising Or Marketing Services industry. This means that EXEL’s stock grew somewhat faster than EXPI’s over the last 12 months.
EXPI's P/E Growth Rating (2) in the Advertising Or Marketing Services industry is significantly better than the same rating for EXEL (90) in the Biotechnology industry. This means that EXPI’s stock grew significantly faster than EXEL’s over the last 12 months.
| EXEL | EXPI | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 77% | 3 days ago 73% |
| Stochastic ODDS (%) | 3 days ago 61% | 3 days ago 75% |
| Momentum ODDS (%) | 3 days ago 66% | 3 days ago 83% |
| MACD ODDS (%) | 3 days ago 74% | 3 days ago 82% |
| TrendWeek ODDS (%) | 3 days ago 66% | 3 days ago 84% |
| TrendMonth ODDS (%) | 3 days ago 60% | 3 days ago 85% |
| Advances ODDS (%) | 3 days ago 64% | 26 days ago 86% |
| Declines ODDS (%) | 24 days ago 62% | 7 days ago 84% |
| BollingerBands ODDS (%) | 3 days ago 76% | 3 days ago 87% |
| Aroon ODDS (%) | 3 days ago 54% | 3 days ago 88% |
EXEL and
Correlation & Price change
A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with SRPT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then SRPT could also see price increases.
| Ticker / NAME | Correlation To EXEL | 1D Price Change % | ||
|---|---|---|---|---|
| EXEL | 100% | +0.59% | ||
| SRPT - EXEL | 36% Loosely correlated | -2.14% | ||
| ALNY - EXEL | 34% Loosely correlated | +3.69% | ||
| TECH - EXEL | 33% Poorly correlated | -1.06% | ||
| MRSN - EXEL | 32% Poorly correlated | +0.44% | ||
| ORMP - EXEL | 32% Poorly correlated | +1.30% | ||
More | ||||
EXPI and
Correlation & Price change
A.I.dvisor indicates that over the last year, EXPI has been loosely correlated with RMAX. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if EXPI jumps, then RMAX could also see price increases.
| Ticker / NAME | Correlation To EXPI | 1D Price Change % | ||
|---|---|---|---|---|
| EXPI | 100% | -0.67% | ||
| RMAX - EXPI | 62% Loosely correlated | +0.95% | ||
| COMP - EXPI | 60% Loosely correlated | +0.14% | ||
| CWK - EXPI | 57% Loosely correlated | -1.79% | ||
| MMI - EXPI | 53% Loosely correlated | -0.32% | ||
| OPEN - EXPI | 53% Loosely correlated | -1.65% | ||
More | ||||